Adults 18 to 65, any sex, with Glabellar Frown Lines. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Evaluate Composite Responder Rate at Month 1 for a Single Dose of AbobotulinumtoxinA Compared to PlaceboPrimary· Month 1 after treatment
Composite responder is defined as a subject who achieves a score of 0 or 1 and at least 2 grades improvement on both the Investigator Live Assessment (ILA) and the Subject Self Assessment (SSA)
Group
Value
95% CI
Experimental
142
Placebo
0
Adverse events — posted to ClinicalTrials.gov
Time frame: 24 weeks.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Experimental
Serious: 4/223 (2%)
Deaths: 0/223
Placebo
Serious: 0/77 (0%)
Deaths: 0/77
Serious adverse events (4 terms)
Reaction
System
Experimental
Placebo
Worsening knee pain
Musculoskeletal and connective tissue disorders
—
—
Acute diverticulitis
Infections and infestations
—
—
Long QT syndrome
Cardiac disorders
—
—
Worsening of hemorrhoids
Gastrointestinal disorders
—
—
Other adverse events (7 terms — click to expand)
Reaction
System
Experimental
Placebo
Headache
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT03935295 — Dysport ® as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis
· Phase 4
· recruiting
NCT04470401 — The Treatment of Shoulder Pain in Hemiplegic Spastic Patients With Botulinum Toxin A
· Phase 4
· completed
Other Galderma R&D trials
Trials by the same sponsor.
NCT07047690 — A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
· Phase 2
· recruiting
NCT07344584 — A Prospective Pilot Study to Evaluate Safety and Effectiveness of GP0122 and GP0124 for Correction of Lines and Wrinkles
· NA
· not yet recruiting
NCT07186413 — A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne
· Phase 3
· recruiting
NCT07398989 — A Clinical Study to Assess Efficacy and Tolerability of a Topical Skincare Product on Adults With Mature, Crepey Skin
· Phase 4
· completed
NCT06988618 — Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Galderma R&D
Last refreshed: 26 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03960957.